The Causes of Pulmonary Fibrosis

The Causes of Pulmonary Fibrosis

While doctors are sometimes able to identify the causes which led to the development of pulmonary fibrosis (PF), there are many instances where the cause can not be determined, making it a case of idiopathic pulmonary fibrosis (IPF). MORE: Study links biology of aging and IPF, opens new paths for possible therapies…

Galapagos Therapy GLPG1690 Excels in Phase 2 IPF Trial, Spurring Further Development

GLPG1690, an investigational therapy developed by Galapagos to treat idiopathic pulmonary fibrosis (IPF), prevented further lung decline in a Phase 2a trial, allowing the Belgian pharmaceutical firm to rapidly move forward with the clinical development of this therapy. The trial, called FLORA (NCT02738801), involved randomly assigning 17 IPF patients treatment with GLPG1690 and…

Experts Will Gather at Inaugural IPF Summit in Boston Aug. 21-23

Key leaders in the idiopathic pulmonary fibrosis therapy development industry, representing large pharma and biotech firms, academia  and contract research organizations, will gather at the inaugural IPF Summit in Boston, Aug. 21-23. This forum will cover the latest in IPF drug development, from late discovery to early clinical studies.

6 Tips for Protecting Your Lungs

We only get one set of lungs so it’s imperative that we look after them. This is even more important with diseases that directly affect the lungs as it could help slow down the progression of the disease and ease the symptoms.  To help you take the best possible care of your lungs,…

Lung Disease and Transplantation: The Harsh Realities

In previous columns, I have alluded to the world of lung diseases and organ transplantation as one that is unique and very different from the life that most people experience. This is especially true for young adults, who naturally focus on building a career, strengthening relationships, starting…

FibroGen Shares Positive Results of Phase 2 Trial of Investigational Therapy Pamrevlumab

A Phase 2 trial testing the investigational therapy pamrevlumab (FG-3019) in patients with idiopathic pulmonary fibrosis (IPF) has shown positive and encouraging results, FibroGen, the drug’s developer, announced. In addition, combining pamrevlumab with the FDA-approved IPF therapies Esbriet (pirfenidone) and Ofev (nintedanib) was found to be safe. These results will be…

5 Benefits of Cannabis Tea for Chronic Illnesses

Medical marijuana is gaining popularity as a complementary medicine to help with many symptoms associated with chronic illnesses. While many people are curious about how marijuana (or cannabis) may help improve their symptoms, they are also reluctant to smoke the substance. However, there are ways that medical marijuana can be administered, including…

4 Common Symptoms of Chest Infections

According to the Better Health Channel, a chest infection affects either the larger airways or the smaller air sacs of the lungs. Most chest infections are viruses, meaning that the body’s immune system is enough to fight the infection on its own. However, with most bacterial chest infections, antibiotics are needed. Chest…